Aveta Biomics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.avetabiomics.com
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Aveta Biomics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06011109
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Treatment of Recurrent GBM With APG-157 Via Expanded Access
- Conditions
- GlioblastomaGlioblastoma Multiforme
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Aveta Biomics, Inc.
- Registration Number
- NCT05551013
Safety and Efficacy of APG-157 in Head and Neck Cancer
Phase 2
Recruiting
- Conditions
- Head and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the Oropharynx
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Aveta Biomics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05312710
- Locations
- 🇺🇸
VAGLAHS, West Los Angeles, Los Angeles, California, United States
🇺🇸University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath